Compare Stocks: VCEL, SYRE, IMVT, and IONS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$33.30 -2.1%	$39.75	$15.56 ▼ $45.42	$6.88B	0.81	1.43 million shs	2.35 million shs
IONS Ionis Pharmaceuticals	$44.50 +1.6%	$54.92	$43.01 ▼ $86.74	$7.40B	0.42	4.15 million shs	6.20 million shs
SYRE Spyre Therapeutics	$85.69 -1.6%	$96.89	$15.49 ▼ $110.18	$7.54B	2.99	1.26 million shs	560,049 shs
VCEL Vericel	$39.71 +1.0%	$42.56	$28.95 ▼ $49.32	$2.03B	1.04	479,084 shs	359,339 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	0.00%	-9.88%	-24.01%	-14.29%	+115.39%
IONS Ionis Pharmaceuticals	0.00%	+0.14%	-28.72%	-45.18%	-30.40%
SYRE Spyre Therapeutics	0.00%	-5.05%	-8.46%	-2.50%	+404.06%
VCEL Vericel	0.00%	-0.77%	-3.57%	-14.10%	+31.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$33.30 -2.1%	$39.75	$15.56 ▼ $45.42	$6.88B	0.81	1.43 million shs	2.35 million shs
IONS Ionis Pharmaceuticals	$44.50 +1.6%	$54.92	$43.01 ▼ $86.74	$7.40B	0.42	4.15 million shs	6.20 million shs
SYRE Spyre Therapeutics	$85.69 -1.6%	$96.89	$15.49 ▼ $110.18	$7.54B	2.99	1.26 million shs	560,049 shs
VCEL Vericel	$39.71 +1.0%	$42.56	$28.95 ▼ $49.32	$2.03B	1.04	479,084 shs	359,339 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	0.00%	-9.88%	-24.01%	-14.29%	+115.39%
IONS Ionis Pharmaceuticals	0.00%	+0.14%	-28.72%	-45.18%	-30.40%
SYRE Spyre Therapeutics	0.00%	-5.05%	-8.46%	-2.50%	+404.06%
VCEL Vericel	0.00%	-0.77%	-3.57%	-14.10%	+31.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.58	Moderate Buy	$44.00	32.13% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$89.20	100.45% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$109.69	28.01% Upside
VCEL Vericel	2.67	Moderate Buy	$58.40	47.07% Upside

Current Analyst Ratings Breakdown

Latest VCEL, SYRE, IMVT, and IONS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive
9/24/2026	IONS Ionis Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$85.00
9/24/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00
9/23/2026	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/22/2026	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$76.00 ➝ $70.00
9/15/2026	IONS Ionis Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$89.00 ➝ $80.00
9/9/2026	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$90.00 ➝ $85.00
9/9/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$123.00
9/8/2026	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$84.00
9/8/2026	IONS Ionis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$110.00 ➝ $104.00

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
IONS Ionis Pharmaceuticals	$944M	7.83	N/A	N/A	$3.02 per share	14.74
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	$7.21 per share	N/A
VCEL Vericel	$306.30M	6.64	$0.56 per share	71.49	$7.01 per share	5.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)
VCEL Vericel	$16.52M	$0.47	84.49	47.27	N/A	7.91%	6.91%	5.02%	11/5/2026 (Estimated)

Latest VCEL, SYRE, IMVT, and IONS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
7/30/2026	Q2 2026	VCEL Vericel	-$0.0289	$0.04	+$0.0689	$0.04	$72.70 million	$77.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	7.27	7.27
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
SYRE Spyre Therapeutics	N/A	18.53	18.53
VCEL Vericel	N/A	5.04	4.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
IONS Ionis Pharmaceuticals	93.86%
SYRE Spyre Therapeutics	80.39%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	1.90%
IONS Ionis Pharmaceuticals	1.81%
SYRE Spyre Therapeutics	15.69%
VCEL Vericel	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
SYRE Spyre Therapeutics	112	87.94 million	74.14 million	Optionable
VCEL Vericel	398	51.21 million	47.32 million	Optionable

VCEL, SYRE, IMVT, and IONS Headlines

Recent News About These Companies

Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain

September 26 at 11:11 PM | finance.yahoo.com

Vericel Corporation (NASDAQ:VCEL) Stock Has Average Price Target of $58.40

September 25 at 6:13 AM | marketbeat.com

Bank of America Corp DE Invests $45.21 Million in Vericel Corporation $VCEL

September 22, 2026 | marketbeat.com

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Vericel: MACI And Regenerative Knee Cartilage

September 14, 2026 | seekingalpha.com

Vericel Corporation $VCEL Shares Sold by Wellington Management Group LLP

September 12, 2026 | marketbeat.com

Scholtz & Company LLC Buys New Stake in Vericel Corporation $VCEL

September 10, 2026 | marketbeat.com

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

September 8, 2026 | globenewswire.com

The Manufacturers Life Insurance Company Makes New Investment in Vericel Corporation $VCEL

September 5, 2026 | marketbeat.com

115,630 Shares in Vericel Corporation $VCEL Bought by Legal & General Group Plc

September 4, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Vericel Corporation $VCEL

September 2, 2026 | marketbeat.com

Jupiter Topco LLC Makes New $4.42 Million Investment in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Man Group plc Buys New Shares in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 31, 2026 | marketbeat.com

Formula Growth Ltd. Makes New $1.15 Million Investment in Vericel Corporation $VCEL

August 28, 2026 | marketbeat.com

Vericel Corporation (VCEL) Stock Price, News, Quote & History - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Vericel (NASDAQ:VCEL) Insider Jonathan Siegal Sells 4,500 Shares

August 1, 2026 | insidertrades.com

Vericel Corporation 2026 Q2 - Results - Earnings Call Presentation

July 31, 2026 | seekingalpha.com

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates

July 30, 2026 | zacks.com

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program

July 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL, SYRE, IMVT, and IONS Company Descriptions

Immunovant NASDAQ:IMVT

$33.30 -0.70 (-2.06%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$33.10 -0.20 (-0.60%)

As of 09/25/2026 07:50 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Ionis Pharmaceuticals NASDAQ:IONS

$44.50 +0.69 (+1.57%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$44.75 +0.25 (+0.56%)

As of 09/25/2026 07:47 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Spyre Therapeutics NASDAQ:SYRE

$85.69 -1.40 (-1.61%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$85.72 +0.03 (+0.03%)

As of 09/25/2026 07:30 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Vericel NASDAQ:VCEL

$39.71 +0.41 (+1.04%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$39.81 +0.10 (+0.25%)

As of 09/25/2026 07:58 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VCEL, SYRE, IMVT, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VCEL, SYRE, IMVT, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VCEL, SYRE, IMVT, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL, SYRE, IMVT, and IONS Company Descriptions

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

Spyre Therapeutics NASDAQ:SYRE

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VCEL, SYRE, IMVT, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VCEL, SYRE, IMVT, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VCEL, SYRE, IMVT, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL, SYRE, IMVT, and IONS Company Descriptions

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

Spyre Therapeutics NASDAQ:SYRE

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools